Piramal Pharma Reports Positive Financial Results for Q2 FY25, Shows Growth in PBT and PAT

Piramal Pharma, a leading player in the pharmaceuticals and drugs industry, has recently announced its financial results for the quarter ending September 2024. The company has shown a positive performance with a score of 10, an improvement from 7 in the last 3 months.

One of the key highlights of the financial report is the growth in Profit Before Tax (PBT) which has increased by 60.0% to Rs 59.01 crore compared to the average PBT of the previous four quarters at Rs 36.87 crore. This indicates a very positive trend in the near term for PBT. Similarly, the Profit After Tax (PAT) has also shown a growth of 55.3% to Rs 22.59 crore, compared to the average PAT of the previous four quarters at Rs 14.55 crore. This is another positive trend for the company in the near term.

In terms of cash flow, Piramal Pharma has generated the highest operating cash flow of Rs 1,004.54 crore in the last three years. This shows that the company has been able to generate higher cash revenues from its business operations.

However, one area of concern for the company is its non-operating income, which is 50.87% of the PBT. This indicates that the company’s income from non-business activities is high, which may not be a sustainable business model.

Overall, Piramal Pharma has shown a strong financial performance in the quarter ending September 2024. With a ‘Hold’ call from MarketsMOJO, investors may want to keep an eye on the company’s future financial reports to make informed decisions.